Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Pathophysiological effects of RhoA and Rho-associated kinase on cardiovascular system

Cai, Anping*; Li, Liwen*; Zhou, Yingling

doi: 10.1097/HJH.0000000000000768
REVIEWS
Buy

In past decades, growing evidence from basic and clinical researches reveal that small guanosine triphosphate binding protein ras homolog gene family, member A (RhoA) and its main effector Rho-associated kinase (ROCK) play central and complex roles in cardiovascular systems, and increasing RhoA and ROCK activity is associated with a broad range of cardiovascular diseases such as congestive heart failure, atherosclerosis, and hypertension. Favorable outcomes have been observed with ROCK inhibitors treatment. In this review, we briefly summarize the pathophysiological roles of RhoA/ROCK signaling pathway on cardiovascular system, displaying the potential benefits in the cardiovascular system with controlling RhoA/ROCK signaling pathway.

Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

*Anping Cai and Liwen Li contributed equally to the writing of this article.

Correspondence to Yingling Zhou, Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Road 2, Guangzhou 510080, China. Tel: +86 20 83827812; fax: +86 20 83827812; e-mail: drcacocolacai@gmail.com

Abbreviations: Ang II, angiotensin II; CHF, congestive heart failure; eNOS, endothelial nitric oxide synthase; GAPs, GTPase-activating proteins; GDP, guanosine diphosphate; GTP, guanosine triphosphate, RBD, Rho-binding domain; Rho, ras homolog gene family, RhoA, ras homolog gene family; member A; ROCK, Rho-associated kinase; VSMC, vascular smooth muscle cells

Received 26 June, 2015

Revised 9 August, 2015

Accepted 8 September, 2015

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.